Zepp Health (NYSE:ZEPP – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.
Insider and Institutional Ownership
52.6% of Zepp Health shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 36.0% of Zepp Health shares are held by company insiders. Comparatively, 25.2% of Bullfrog AI shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Zepp Health and Bullfrog AI, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zepp Health | 1 | 0 | 1 | 0 | 2.00 |
| Bullfrog AI | 1 | 0 | 0 | 0 | 1.00 |
Risk & Volatility
Zepp Health has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.29, suggesting that its stock price is 329% less volatile than the S&P 500.
Profitability
This table compares Zepp Health and Bullfrog AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zepp Health | -15.48% | -15.00% | -6.07% |
| Bullfrog AI | N/A | -273.24% | -208.55% |
Valuation and Earnings
This table compares Zepp Health and Bullfrog AI”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zepp Health | $258.90 million | 0.92 | -$40.07 million | ($2.51) | -6.54 |
| Bullfrog AI | $120,000.00 | 104.90 | -$6.50 million | ($0.63) | -1.58 |
Bullfrog AI has lower revenue, but higher earnings than Zepp Health. Zepp Health is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.
Summary
Zepp Health beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.
About Zepp Health
Zepp Health Corporation operates as a smart wearable and health technology company worldwide. The company operates in two segments: Self-Branded Products and Others, and Xiaomi Wearable Products. It empowers users to live lives by optimizing health, fitness, and wellness journeys through its consumer brands, Amazfit, Zepp Clarity, and Zepp Aura. The company through its proprietary Zepp Digital Management Platform, which includes the Zepp OS, AI chips, biometric sensors, and data algorithms, delivers cloud-based 24/7 actionable insights and guidance to help users attain wellness goals. The company offers smart bands, watches, modules, and scales; and associated accessories, smart hearable products, sportswear, home fitness equipment, home appliances, and smart watch accessories. It also provides charts and graphs to display analysis of the activity and biometric data collected from users through its Zepp Life and Zepp mobile apps. It offers its products under the Amazfit and Zepp brand names in approximately 90 countries. The company was formerly known as Huami Corporation and changed its name to Zepp Health Corporation in February 2021. Zepp Health Corporation was founded in 2013 and is headquartered in Hefei, the People's Republic of China.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for Zepp Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zepp Health and related companies with MarketBeat.com's FREE daily email newsletter.
